Sanofi-aventis has reported an increase in net sales by 11.2% to E7.43 billion in the second quarter of 2009, as compared to the net sales of the prior year.
The company has reported an increase in net sales for the first half of the year by 6.7% to E14.54 billion, as compared to the net sales in the first half of the prior year. The consolidated net income for the first half of 2009 was E2.63 billion, as compared to E2.33 billion for the first half of 2008. The consolidated earnings per share for the first half of 2009 was E2.02, as against E1.78 for the first half of 2008.
The company has reported that the net sales for the Pharmaceuticals business were up 7.3% at E6.72 billion for the second-quarter. First-half net sales were up 3% at E13.2 billion.
Christopher Viehbacher, CEO of Sanofi-aventis, said: “The group delivered very strong results in the second quarter, driven by solid growth of key pharmaceutical brands and vaccines, strong sales in emerging markets and recent acquisitions. Multaq has just been launched in the US in July. The strong progression of our earnings has led us to raise our guidance for 2009 to EPS5 growth of around 10%.
Since the beginning of the year, we have launched a new R&D approach to increase innovation, we have strengthened our growth platforms through acquisitions, and we are moving forward with the transformation of our company. Those achievements constitute another step toward our vision of becoming a leading diversified global healthcare company, with a sustainable growth profile by 2013,” he added.